Hope Funds For Cancer Research – Trademark Portfolio

Entity Type: 03

Hope Funds For Cancer Research holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 36 (Insurance & Financial) — 2 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include THE HOPE FUNDS FOR CANCER RESEARCH and THE HOPE FUNDS FOR CANCER RESEARCH COURAGE COMPASSION CONVICTION CARE CURE. The owner is based in Newport, RI.

Suite 208

174 Bellevue Avenue

Newport, RI 02840

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Hope Funds For Cancer Research's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

36
Insurance & Financial (2 filings)

Insurance; financial affairs; monetary affairs; real estate affairs

Frequently Asked Questions

How many trademarks does Hope Funds For Cancer Research have?

Hope Funds For Cancer Research has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does Hope Funds For Cancer Research file in?

Hope Funds For Cancer Research files trademarks across 1 Nice Classification class. The most active classes are Class 36 (Insurance & Financial). Class 36 covers insurance; financial affairs; monetary affairs; real estate affairs.

What are Hope Funds For Cancer Research's most well-known trademarks?

Hope Funds For Cancer Research's registered trademark portfolio includes well-known marks such as THE HOPE FUNDS FOR CANCER RESEARCH and THE HOPE FUNDS FOR CANCER RESEARCH COURAGE COMPASSION CONVICTION CARE CURE. These are among 2 currently registered trademarks in the portfolio.

What is Hope Funds For Cancer Research's trademark registration success rate?

Hope Funds For Cancer Research has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.